New long-term data for Roche ’s Vabysmo show sustained retinal drying and vision improvements in retinal vein occlusion (RVO)
Vabysmo sustained robust drying of retinal fluid, often associated with distorted or blurry visionUp to 60% of people receiving Vabysmo were able to extend treatment intervals to three or four months apartDetailed results from two global Phase III RVO studies will be presented at Angiogenesis, Exudation, and Degeneration 2024Vabysmo is approved in the US for RVO, and in more than 90 countries around the world for people living with nAMD and DMEBasel, 1 February 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today new 72-week data from two global Phase III studies, BALATON and COMINO, evaluating Vabysmo® (faricimab) i...
Source: Roche Investor Update - February 1, 2024 Category: Pharmaceuticals Source Type: news

New long-term data for Roche ’s Vabysmo show sustained retinal drying and vision improvements in retinal vein occlusion (RVO)
Vabysmo sustained robust drying of retinal fluid, often associated with distorted or blurry visionUp to 60% of people receiving Vabysmo were able to extend treatment intervals to three or four months apartDetailed results from two global Phase III RVO studies will be presented at Angiogenesis, Exudation, and Degeneration 2024Vabysmo is approved in the US for RVO, and in more than 90 countries around the world for people living with nAMD and DMEBasel, 1 February 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today new 72-week data from two global Phase III studies, BALATON and COMINO, evaluating Vabysmo® (faricimab) i...
Source: Roche Media News - February 1, 2024 Category: Pharmaceuticals Source Type: news

Tensions are bubbling up at thirsty Arizona alfalfa farms as foreign firms exploit unregulated water
A blanket of bright green alfalfa spreads across western Arizona's McMullen Valley, ringed by rolling mountains and warmed by the hot desert sun. Matthew Hancock's family has used groundwater to grow forage crops here for more than six decades. They're long accustomed to caprices of Mother Nature…#arizona #mcmullenvalley #matthewhancock #wenden #emirati #aldahra #hancock #phoenix #western #unitednations (Source: Reuters: Health)
Source: Reuters: Health - November 28, 2023 Category: Consumer Health News Source Type: news

Do women prefer having female radiologists perform breast ultrasound?
Most women undergoing breast ultrasound are unconcerned about whether a radiologist is male or female, according to research published November 8 in PLOS One.  A team led by Elisabeth Sartoretti, MD, from the University of Lucerne in Switzerland found that nearly three out of four women reported that it made no difference whether a female or male radiologist performed a breast ultrasound exam.  “It would appear that women examined by male radiologists are less selective about the sex of the examining radiologist,” Sartoretti and colleagues wrote.  The researchers noted that there is a trend toward fewer male radiolo...
Source: AuntMinnie.com Headlines - November 13, 2023 Category: Radiology Authors: Amerigo Allegretto Tags: Subspecialties Womens Imaging Breast Imaging Source Type: news

[Ad hoc announcement pursuant to Art. 53 LR] FDA approves Roche ’s Vabysmo for the treatment of retinal vein occlusion (RVO)
RVO is the third indication for Vabysmo, in addition to neovascular or ‘wet’ age-related macular degeneration and diabetic macular edemaApproval is based on two phase III studies demonstrating early and sustained vision improvements that were non-inferior to afliberceptVabysmo also demonstrated rapid and robust drying of retinal fluidAdditional U.S. label update across indications includes information on rare post-marketing reports of retinal vasculitis and/or retinal vascular occlusion; reporting rate isin line withother broadly used intravitreal treatmentsBasel, 27 October 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) an...
Source: Roche Investor Update - October 27, 2023 Category: Pharmaceuticals Source Type: news

[Ad hoc announcement pursuant to Art. 53 LR] FDA approves Roche ’s Vabysmo for the treatment of retinal vein occlusion (RVO)
RVO is the third indication for Vabysmo, in addition to neovascular or ‘wet’ age-related macular degeneration and diabetic macular edemaApproval is based on two phase III studies demonstrating early and sustained vision improvements that were non-inferior to afliberceptVabysmo also demonstrated rapid and robust drying of retinal fluidAdditional U.S. label update across indications includes information on rare post-marketing reports of retinal vasculitis and/or retinal vascular occlusion; reporting rate isin line withother broadly used intravitreal treatmentsBasel, 27 October 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) an...
Source: Roche Media News - October 27, 2023 Category: Pharmaceuticals Source Type: news

Roche ’s Vabysmo maintained vision improvements with extended treatment intervals up to four months for people with retinal vein occlusion (RVO) in phase III studies
Vabysmo showed robust and sustained retinal drying up to 72 weeks and a safety profile consistent with previous studiesRegulatory applications for Vabysmo in RVO are under review by health authorities around the world; if approved, RVO would be the third indication in addition to nAMD and DMEVabysmo is the first and only treatment that targets and inhibits two signalling pathways linked to a number of vision-threatening retinal conditionsBasel, 10 October 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced positive topline long-term results from the global phase III BALATON and COMINO studies, evaluating extended tre...
Source: Roche Media News - October 10, 2023 Category: Pharmaceuticals Source Type: news

Roche ’s Vabysmo maintained vision improvements with extended treatment intervals up to four months for people with retinal vein occlusion (RVO) in phase III studies
Vabysmo showed robust and sustained retinal drying up to 72 weeks and a safety profile consistent with previous studiesRegulatory applications for Vabysmo in RVO are under review by health authorities around the world; if approved, RVO would be the third indication in addition to nAMD and DMEVabysmo is the first and only treatment that targets and inhibits two signalling pathways linked to a number of vision-threatening retinal conditionsBasel, 10 October 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced positive topline long-term results from the global phase III BALATON and COMINO studies, evaluating extended tre...
Source: Roche Investor Update - October 10, 2023 Category: Pharmaceuticals Source Type: news

The Man Who Thinks He Can Live Forever
In a neat little neighborhood in Venice, Calif., there’s a block of squat, similar homes, filled with mortals spending their finite days on the planet eating pizza with friends, blowing out candles on birthday cakes, and binging late-night television. Halfway down the street, there’s a cavernous black modern box. This is where Bryan Johnson is working on what he calls “the most significant revolution in the history of Homo sapiens.”  [time-brightcove not-tgx=”true”] Johnson, 46, is a centimillionaire tech entrepreneur who has spent most of the last three years in pursuit of a si...
Source: TIME: Health - September 20, 2023 Category: Consumer Health News Authors: Charlotte Alter Tags: Uncategorized feature Source Type: news

The Great Salt Lake is shrinking rapidly, and Utah has failed to stop it, a lawsuit contends
Utah officials have pushed the Great Salt Lake to the brink of an ecological collapse because they allowed upstream water to be diverted for decades to farmers growing alfalfa, hay and other crops, according to a lawsuit filed Wednesday by a coalition of environmental groups. The conservationists…#utah #greatsaltlake #mississippiriver #nt #legislature #earthjustice #utahriverscouncil #utahphysicians #brianmoench #emmawilliams (Source: Reuters: Health)
Source: Reuters: Health - September 7, 2023 Category: Consumer Health News Source Type: news

Amid record heat, solar farms help ease the strain on U.S. power grids
Rosamond, California — Next to the rows of alfalfa, another type of farm is taking root in Southern California's Kern County, one that's harvesting clean, renewable energy. Solar Star, one of the largest solar farms in the U.S., has a peak output of 586 megawatts. "These panels track the sun all…#rosamond #southerncalifornia #kerncounty #solarstar #aliciaknapp #bherenewables #knapp #pjminterconnection #loreleioviatt #cbsnews (Source: Reuters: Health)
Source: Reuters: Health - July 28, 2023 Category: Consumer Health News Source Type: news

New clinical and real-world data for Roche ’s Vabysmo at ASRS reveal improved outcomes for people with two leading causes of vision loss
Late-breaking post-hoc data indicateVabysmo leads to less fibrosis, which may negatively impact vision, thanaflibercept in people with diabetic macular edema (DME)Real-world data reinforce that first-lineVabysmo use improves outcomes and extends treatment intervals rapidly during the first four months for people withneovascular or ‘wet’ age-related macular degeneration (nAMD) and DMEClinical data reiterateVabysmo ’s positive anatomical outcomes, including reduced blood vessel leakage in the macula and greater and faster retinal fluid controlVabysmo is currently approved in over 70 countries to treatnAMD and DME, with...
Source: Roche Media News - July 20, 2023 Category: Pharmaceuticals Source Type: news

New clinical and real-world data for Roche ’s Vabysmo at ASRS reveal improved outcomes for people with two leading causes of vision loss
Late-breaking post-hoc data indicateVabysmo leads to less fibrosis, which may negatively impact vision, thanaflibercept in people with diabetic macular edema (DME)Real-world data reinforce that first-lineVabysmo use improves outcomes and extends treatment intervals rapidly during the first four months for people withneovascular or ‘wet’ age-related macular degeneration (nAMD) and DMEClinical data reiterateVabysmo ’s positive anatomical outcomes, including reduced blood vessel leakage in the macula and greater and faster retinal fluid controlVabysmo is currently approved in over 70 countries to treatnAMD and DME, with...
Source: Roche Investor Update - July 20, 2023 Category: Pharmaceuticals Source Type: news

How the Tech Behind a COVID-19 Vaccine is Helping Save Bees
After more than a decade in the industry, commercial beekeeper Liana Teigen Moreno thought she knew what she was doing when it came to making honey. A hipster pixie with a platinum crew cut and bright blue eyes, Teigen tends to 800 beehives in northern Florida. Her experience at the University of Florida’s Honey Bee Research Lab in Gainesville taught her everything she needed to know about bee diseases, knowledge that came in handy late last year when she realized that an insidious parasite that she had first learned about working her way through college as a part-time beekeeper had decimated her hives—despite ...
Source: TIME: Science - July 3, 2023 Category: Science Authors: Aryn Baker and Video by Andrew. D Johnson Tags: Uncategorized climate climate change Climate Is Everything COVID-19 feature Food & Agriculture healthscienceclimate Londontime Source Type: news

FDA accepts application for Roche ’s Vabysmo for the treatment of retinal vein occlusion (RVO)
Acceptance based on two phase III studies that demonstrated early and sustained vision improvement with Vabysmo, meeting primary endpoint of non-inferiority compared to afliberceptApplication was further supported by data showing Vabysmo achieved rapid and robust drying of retinal fluidIf approved, RVO would be the third indication for Vabysmo in addition to neovascular or ‘wet’ age-related macular degeneration (nAMD) and diabetic macular edema (DME)Vabysmo is currently approved in 60 countries to treat nAMD and DME, with nearly one million doses distributed globallyBasel, 9 May 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY...
Source: Roche Investor Update - May 9, 2023 Category: Pharmaceuticals Source Type: news